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Mutations in Human ARF Exon 2 Disrupt Its
Nucleolar Localization and Impair Its Ability
to Block Nuclear Export of MDM2 and p53
p53 is required for ARF to induce G1 cell cycle arrest
(Kamijo et al., 1997) provide genetic evidence that ARF
is a bona fide tumor suppressor and acts upstream
of p53. Biochemical evidence supporting the genetic
interaction between ARF and p53 comes from the find-
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Chapel Hill, North Carolina 27599 ing that ARF physically interacts with MDM2 and conse-
quently stabilizes p53 (Kamijo et al., 1998; Pomerantz
et al., 1998; Stott et al., 1998; Zhang et al., 1998). The
molecular pathway by which ARF stabilizes p53 is notSummary
clear at present. One possible mechanism—ARF-pro-
moting MDM2 degradation—was proposed based onThe mammalian ARF-INK4a locus uniquely encodes
the observation that coexpression of ARF with MDM2two cell cycle inhibitors by using separate promoters
in HeLa cells reduces the half-life of MDM2 (Zhang etand alternative reading frames. p16INK4a maintains the
al., 1998). However, experiments in other cell types haveretinoblastoma protein in its growth suppressive state
yielded conflicting results. Ectopic expression of ARFwhile ARF stabilizes p53. We report that human ARF
in nonvirally transformed human cells or activation ofprotein predominantly localizes to the nucleolus via a
ARF expression by E1A or myc in MEF’s induced MDM2sequence within the exon 2–encoded C-terminal do-
accumulation (de Stanchina et al., 1998; Kamijo et al.,main and is induced to leave the nucleolus by MDM2.
1998; Stott et al., 1998; Zindy et al., 1998) suggest thatARF forms nuclear bodies with MDM2 and p53 and
ARF may antagonize MDM2 function through differentblocks p53 and MDM2 nuclear export. Tumor-associ-
mechanisms, that is, with or without degrading MDM2,ated mutations in ARF exon 2 disrupt ARF’s nucleolus
and that the MDM2-ARF interaction may be affected bylocalization and reduce ARF’s ability to block p53 nu-
viral transformation.clear export and to stabilize p53. Our results suggest
The genetic alterations at the ARF-INK4a locus occuran ARF-regulated MDM2-dependent p53 stabilization
in a wide spectrum of human cancers, both familial andand link the human tumor-associated mutations in
sporadic, at a frequency estimated to be close to thatARF with a functional alteration.
of p53 locus (Kamb et al., 1994; Nobori et al., 1994; and
recently compiled by Foulkes et al., 1997; Ruas and
Peters, 1998). Many alterations at the ARF-INK4a locusIntroduction
involve homozygous deletions, which simultaneously
disrupt both ARF and INK4a genes. There are also fre-Upstream regulators of p53 activity have been elusive;
until very recently MDM2 was the only cellular protein quent mutations predicted to alter both the INK4a and
ARF proteins, including frameshift microdeletions/inser-known to physically interact with and control the func-
tion of p53 (Prives, 1998). MDM2 binds to and abrogates tions and nucleotides substitutions, which appear pri-
marily clustered in the 59 portion of exon 2 shared byp53 function by either targeting p53 for degradation in
the cytoplasm or by repressing p539s transcriptional ARF and INK4a. That ectopic expression of the exon
1b–encoded N-terminal domain of ARF is sufficient toactivity in the nucleus (reviewed in Levine, 1997; Prives,
1998). It is not clear whether these two geographically cause cell cycle arrest (Quelle et al., 1997; Zhang et al.,
1998) has led to a notion that only INK4a is frequentlyseparate biochemical activities of MDM2 are related to
a common pathway of p53 regulation. altered by mutations in exon 2, while ARF is not. This
notion is, however, tainted by the lack of a specificAny factor that interacts with or controls the function
of MDM2 is likely to be a regulator of p53 acting further function attributable to the exon 2–encoded ARF C-ter-
minal domain, which might be affected by mutation. Weupstream. One such regulator is the tumor suppressor
ARF. The ARF protein is encoded by the ARF-INK4a report here that exon 2 of human ARF is required for its
localization to the nucleolus, for the formation of ARF-locus of human chromosome 9p21 that also encodes
p16INK4a, an inhibitor of the CDK4/6 (Serrano et al., 1993). MDM2-p53 nuclear bodies, and for the full activity of
ARF in blocking p53 nuclear export and stabilizing p53.The ARF-INK4a locus contains two unique first exons,
designated 1a and 1b, which are spliced into common Hence, the function of ARF, like that of INK4a, is not only
frequently disrupted in human cancer by homozygousexons 2 and 3 (reviewed in Sherr, 1998; see also Figure
2A). The exon 1a–exon 2–exon 3 transcript encodes locus deletions, but also by point mutations.
INK4a (Serrano et al., 1993), while the exon 1b–exon
2–exon 3 transcript specifies ARF in an alternative read- Results
ing frame, which results in a protein bearing no amino
acid sequence similarity to INK4a (Quelle et al., 1995). ARF Protein Is Localized Predominantly
The facts that ARF null mice develop spontaneous tu- to the Nucleolus
mors at an early age and that the presence of wild type We and others observed that human ARF protein is
predominantly localized to the nucleolus (Figure 1A;
Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al.,§ To whom correspondence should be addressed (e-mail: yxiong@
email.unc.edu). 1998). To confirm this, we examined the subcellular lo-
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Figure 1. ARF C-Terminal Domain Mediates Nucleolar Localization
(A) ARF localizes to the nucleolus. Subcellular localization of ARF protein was examined by indirect immunofluorescence staining, in either
untransfected HeLa cells (a), or U2-OS and Saos-2 cells transiently transfected with a plasmid or infected with adenovirus expressing indicated
proteins. Cells were fixed and stained with rabbit a-ARF antibody followed by staining with rhodamine-conjugated a-rabbit IgG antibody.
(B) Protein sequence comparison of human ARF and mouse ARF. Schematic diagram of human ARF structure and various ARF deletion
mutants used in this study.
(C) Mapping of nucleolar localization signal sequence. Subcellular localization of ARF protein was examined in U2-OS cells transiently
transfected with plasmid DNA expressing myc-tagged wild-type ARF and various ARF deletion mutants.
(D) U2-OS and Saos-2 cells were transfected with plasmids expressing either GFP or ARF85–101-GFP fusion protein. The subcellular localization
of both proteins was determined by fluorescence microscopy.
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calization of ARF protein in several different cell types is remarkably divergent from its murine homolog, shar-
ing only 49% amino acid sequence identity over 132and under different expression conditions. ARF is ex-
pressed at a relatively high level in HeLa cells and is residues (Figure 1B). Notably, neither of the clusters of
basic residues in human ARF is conserved in mouselocalized to the nucleolus (Figure 1Aa). The human os-
teosarcoma cell line, U2-OS, which expresses an unde- ARF, which instead contains one stretch of basic resi-
dues in exon 1b (R29SRRPR34). Consistent with this ob-tectable level of endogenous ARF, also exhibits nucleo-
lus staining for transiently transfected ARF (Figure 1Ab) servation, deletion of residues 26 to 37, but not deletion
of the exon 2 domain, from murine ARF resulted in aand ARF expressed using adenovirus as a vector (Figure
1Ac), indicating that ARF, even at high levels of expres- disruption of its nucleolar localization (C. Sherr, personal
communication).sion, is still predominantly localized to the nucleolus.
Saos-2 cells, which, like the HeLa cells, lack both p53
and pRb function show similar staining (Figure 1Ad); Tumor-Derived Mutations Disturb ARF Localization
thus, ARF nucleolus localization is not affected by p53 This ARF exon 2–encoded localization sequence led us
or Rb function. To rule out the localization as an artifact to reexamine previously reported exon 2 mutations. Of
of overexpression, Saos-2 cells (Figure 1Af) and normal the 268 alterations compiled for ARF exon 2 (Foulkes
human fibroblasts (NHF, Figure 1Ah) were infected with et al., 1997; Ruas and Peters, 1998), 72 are deletions/
an adenovirus expressing E2F1, an activator of ARF insertions that cause frameshifts (denoted by an “X” in
gene expression (Bates et al., 1998). E2F1, but not con- Figure 2A). Forty-five of these occurred either within
trol adenovirus, significantly induced endogenous ARF or upstream of the nuclear and nucleolar localization
expression, which showed predominantly nucleolus lo- sequence and would therefore be predicted to disrupt
calization. The ARF antibody specificity is confirmed by the nucleolar localization of ARF. To test this prediction,
the negative staining of untransfected and uninfected we generated two ARF frameshift mutants and exam-
cells. ined their subcellular localization. One mutation, a single
base deletion (C259 in ARF or C216 in p16), was identi-
fied in a patient with non–small cell lung cancer andARF Exon 2 Encodes a Sequence Necessary
and Sufficient for Nucleolar Localization caused a frameshift at ARF codon 86, resulting in an
ARF1–86-p1673–156 chimeric protein. The other, a singleTo identify the sequence mediating ARF nucleolar local-
ization, we examined subcellular localization of ARF de- base deletion (G282 in ARF or G239 in p16), was identi-
fied in a patient with esophageal squamous cell carci-letion mutants (Figures 1B and 1C). ARF lacking exon
2–encoded C-terminal sequences was diffused through- noma and caused a frameshift at ARF codon 94, re-
sulting in an ARF1–94-p1680–156 chimeric protein. Whenout both the cytoplasm and nucleoplasm without clear
nucleolar accumulation (Figure 1Cb). In contrast, N-ter- expressed in U2-OS cells, both mutants showed disrup-
tion of ARF’s normal nuclear and nucleolar localizationminal deletion does not detectably affect ARF’s nucleo-
lar localization (Figure 1Cc), confirming the presence (Figures 2Bb and 2Bc).
In addition to frameshift mutations, the ARF-INK4aof a nucleolar localization sequence within the exon 2
domain. The C-terminal domain also showed cyto- locus also suffers frequent missense substitution muta-
tions within the sequence shared by INK4a and ARF.plasmic accumulation not observed with wild-type ARF
(compare Figure 1Ca with Figure 1Cc). It is unclear One of the most frequently mutated codons affects Arg-
98 in ARF and Asp-84 in INK4a, which are reportedlywhether this reflects simple diffusion of the 6.7 kDa
protein or contributions to ARF’s nucleolar localization mutated to one of three different residues (Pro, Gln, and
Leu) in at least seven tumors. Interestingly, Asp-84Nby sequence within exon 1b (see below). Removal of
the C-terminal 16 (Figure 1Cd) or 31 residues (Figure mutation of INK4a has no detectable effect on its inhibi-
tory activity toward the cyclin D1/CDK4 enzyme (Koh et1Ce) had no obvious effect on ARF’s nucleolar localiza-
tion. However, a deletion removing 50 C-terminal resi- al., 1995). Mutation of ARF Arg-98 to any of the three
residues caused diffusion of ARF in both the cytoplasmdues completely abolished ARF’s nucleolar localization
(Figure 1Cf). These experiments identified a sequence— and the nucleus (Figures 2Bd, 2Be, and 2Bf). Nucleolus
staining was still obvious, indicating that these missensebetween residues 83 and 101 within exon 2 of ARF—
necessary for localizing ARF to the nucleolus. mutations might have a less severe effect on a nucleo-
lus-dependent ARF function than the truncating muta-Between residues 83 and 101 of human ARF are two
potential nuclear and/or nucleolar localization signals tions.
Reports have also accumulated of tumor-associated(NLS/NOS) made up of basic residues (R87RPR90 and
R96ARR99; Figure 1B). To directly test this possibility, we mutations, which alter ARF sequence, but not INK4a
(Figure 2A, amino acids shown in red). While the effectfused the 17 amino acids of human ARF residues 85 to
101 (underlined in Figure 1B) with the reporter protein of individual ARF missense mutations remains to be
determined, some INK4a-silent, ARF-nonsense muta-GFP and determined the subcellular localization of the
fusion protein. Unfused GFP is evenly distributed through- tions are predicted to alter ARF’s localization based on
our deletion and mutational analysis. For example, aout both the nucleus and cytoplasm and was evidently
excluded from the nucleolus (Figures 1Da and 1Dc). single base substitution C219T in INK4a, or C262T in
ARF, reported in two different patients (one with breastThe ARF85–101-GFP fusion protein exhibited significant
accumulation both in the nucleoplasm and nucleolus cancer and one with melanoma [Ruas and Peters, 1998])
resulted in a silent mutation at the INK4a codon for Ala-(Figures 1Db and 1Dd), demonstrating that residues 85
through 101 are also sufficient for localizing a heterolo- 73, but a nonsense mutation at the ARF codon for Arg-
88, which would almost certainly disrupt ARF’s nucleolargous protein to the nucleus and nucleolus. Human ARF
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Figure 2. Human Cancer-Associated Muta-
tions in Exon 2 Alter the Subcellular Location
of ARF and Reduce ARF’s Ability to Stabilize
p53
(A) The genomic structure of the human ARF-
INK4a locus and the entire 68 amino acid resi-
dues encoded by exon 2 are shown. The ma-
jority of previously reported mutations in
INK4a occurred in exon 2 and preferentially
target the 59 portion that is shared with ARF
(Foulkes et al., 1997; Ruas and Peters, 1998).
X defines frameshift mutations caused by a
deletion/insertion. Z indicates a termination
codon caused by a nonsense mutation.
Amino acid residues shown in red represent
INK4a-silent, ARF-specific mutations. Two
frameshift mutations and three missense mu-
tations generated and used in this study are
highlighted. The number in superscript rep-
resents mutations of the same residue in mul-
tiple tumors. Sequences required for ARF
nucleolar localization as delineated from de-
letion analysis (Figure 1) are underlined.
(B) Subcellular locations of two frameshift
and three point mutation ARF mutants were
examined in U2-OS cells.
(C) U2-OS cells were first infected with ade-
novirus expressing MDM2 protein (Ad-MDM2),
then transiently transfected with plasmids ex-
pressing p53 and individual ARF proteins as
indicated. Lysates were prepared from each
infected/transfected cell population 24 hr
after transfection and separated by SDS-
PAGE. Different portions of the same blot
were immunoblotted with antibodies recog-
nizing MDM2, p53, ARF, or tubulin. The amount
of p53 protein from each infected/transfected
cell population was quantitated on a densi-
tometer and normalized relative to the
amount of p53 protein present in cells trans-
fected with p53 and an empty vector DNA.
localization based on our deletion analysis. Similarly, a is deceptively higher since nearly all of the cells were
C249T mutation in INK4a or C292T in ARF reported in infected by MDM2 adenovirus while only a fraction re-
two different patients (one with non–small cell lung can- ceived the plasmid DNA expressing p53 and ARF. In
cer and one with lung adenocarcinoma) resulted in a this setting, the level of p53 protein from transient trans-
silent mutation at the INK4a codon for His-83, but a fection into the Ad-MDM2-infected cells was used as a
nonsense mutation at the ARF codon for Arg-98. To- standard for comparison (lane 1). The p53 protein level
gether, these results indicate that some exon 2 muta- was increased about 150% when cotransfected with an
tions can selectively affect ARF. These findings also ARF-expressing plasmid (lane 2). However, when co-
bear a diagnostic implication: disruption of ARF’s nucle- transfected with equal amounts of plasmid DNA ex-
olar localization may provide a simple and sensitive pressing the exon 1b–encoded ARF N-terminal domain
assay for detecting mutations in exon 2. (lane 3) or tumor-associated ARFR98L (lane 4) and ARFR98Q
(lane 5) mutant proteins, the level of p53, albeit still
higher than that accumulated in the absence of ARF, isMutations in Exon 2 Reduce ARF’s Ability
reproducibly half that seen with wild-type ARF cotrans-to Stabilize p53
fection. As a control, tubulin levels were not affected byWe next determined whether mutations altering ARF’s
the transfection. These results indicate that the ARFnucleolar localization affect ARF’s stabilization of p53.
N-terminal domain is capable of inhibiting MDM2-medi-U2-OS cells were infected with MDM2 adenovirus to
ated p53 degradation when overexpressed, but deletionprovide a uniform background of MDM2 protein in the
or tumor-derived mutations in the exon 2 domain reducecell population. Then, cells were transfected with plas-
ARF’s ability to stabilize p53. Hence, the full activity ofmids expressing the p53 and ARF proteins. The level of
ARF in stabilizing p53 requires both the N- and C-termi-each protein was determined by direct immunoblotting
of total cell lysate (Figure 2C). The level of MDM2 protein nal domains.
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Figure 3. MDM2 Induces ARF to Relocate from Nucleolus to Nucleoplasm and ARF Colocalizes with MDM2 and p53 to Form Nuclear Bodies
(A) HeLa cells were infected with Ad-MDM2 at m.o.i. of 1. Cells were fixed and stained with antibodies specific to MDM2 and ARF 24 hr after
infection. Note that in MDM2-positive cells, ARF is relocated to the nucleus. MDM2-negative cells and the specificity of the a-MDM2 antibody
are confirmed by the negative staining of two cells in the same field.
(B) Saos-2 cells were singly or doubly infected with adenoviruses expressing p53, MDM2, and ARF as indicated. Cells were fixed and stained
with antibodies specific to each protein, followed by staining with an appropriate fluorochrome-conjugated secondary antibody, 24 hr after
infection. The specificity of each antibody is confirmed by the negative staining of cells in the same field.
(C) Four cell lines with different levels of MDM2 were infected with Ad-E2F1 or a control empty adenovirus. (SJSA and U2-OS have MDM2
amplification; NHF-1 is low in MDM2; Saos-2 is p53 and MDM2 negative). Cells were fixed and stained as described before. Note that E2F1
induced ARF expression in all cell lines. E2F1-induced ARF was relocated to the nucleoplasm, and there was a formation of nuclear bodies
in MDM2- and p53-positive SJSA, U2-OS, and NHF-1 cells, but not in Saos-2 cells.
MDM2 Induces ARF to Relocate from the Nucleolus indicates that in these MDM2-positive cells, ARF is ex-
cluded from nucleolus (notice the dark holes in the ARFto the Nucleoplasm
Looking for the mechanism linking ARF’s subcellular and MDM2 staining, which match with the nucleoli seen
in the phase contrast). To determine the generality of thislocalization and its stabilization of p53, we examined the
subcellular localization of p53, ARF, and MDM2 when regulation and exclude possible aberrant ARF-MDM2
interactions in HeLa cells caused by the viral transforma-expressed in all possible combinations. HeLa cells,
which accumulate a high level of ARF protein in the tion, we determined the subcellular localization of these
two proteins coexpressed in p53-negative Saos-2 cells,nucleolus and have an undetectable level of MDM2,
were infected with Ad-MDM2 followed by staining for which express undetectable levels of ARF and MDM2.
As expected, when singly expressed, ARF was localizedboth ARF and MDM2. The infection was carried out at
low multiplicity of infection (m.o.i.) to allow examination to the nucleolus (Figure 3B, column 3), while MDM2 and
p53 distributed uniformly throughout the nucleus butof both MDM2-positive and -negative cells in the same
viewing field. While ARF remains in the nucleolus in all were evidently excluded from the nucleolus (Figure 3B,
columns 1 and 2; Table 1). Consistent with MDM2-medi-MDM2-negative cells, it was moved to the nucleoplasm
in MDM2-positive cells (Figure 3A). Close examination ated p53 degradation, coexpression of MDM2 and p53
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p53 with ARF did not change the localization of eitherTable 1. Protein Localization and Nuclear Export
protein: p53 remains evenly distributed throughout the
Subcellular Localizationa nucleus, while ARF is still localized predominantly to the
Nuclear Nucleolus Nuclear nucleolus (Figure 3B, column 5). However, in Ad-MDM2
Infections Staining Staining Bodies and Ad-ARF double infected cells, ARF, as in MDM2-
infected HeLa cells, moved out of the nucleolus and is1. Ad-p53 98% 0% 0%
evenly distributed in the nucleus.2. Ad-MDM2 100% 0% 0%
3. Ad-ARF weak 100% 0% To determine whether the MDM2-induced ARF relo-
4. Ad-p53 95% 0% 0% cation occurs under physiological conditions, we ec-
Ad-ARF weak 100% topically expressed E2F1 to induce the expression of
5. Ad-MDM2 90% 5% 0%
endogenous ARF in cell lines with different levels ofAd-ARF 86% 52%
endogenous MDM2 protein. Due to the lack of a fourth6. Ad-MDM2b 100% 0% 9%
fluorescence color, Ad-E2F1 infection was not con-Ad-p53 100% 0%
7. Ad-MDM2 colocalized, 0% 87% firmed directly by a-E2F1 staining; instead, it was indi-
Ad-p53 punctate rectly determined by the ARF staining and a-E2F1 immu-
Ad-ARF noblotting (data not shown). In SJSA osteosarcoma cells
Nuclear Exportc and U2-OS cells, both of which have MDM2 amplifica-
tion, infection of Ad-E2F1, but not control virus, inducedInfections/Transfection Nuclear Export
an evident expression of endogenous ARF. In about 90
8. Ad-p53 p53: 90% out of 100 cells counted for each of these cell lines, ARF
Ad-ARF ARF: weak
was localized to the nucleoplasm, not the nucleolus9. Ad-MDM2 MDM2: 85%
(Figure 3C). In NHF cells, E2F1-induced ARF was evi-Ad-ARF ARF: weak
dently accumulated in the nucleoplasm in a significant10. Ad-MDM2 MDM2: 91%
Ad-p53 p53: 51% population of cells (about 60 out of 100 cells counted;
11. Ad-MDM2 p53: 7% Figure 3C). In the NHF cells where ARF was moved out
Ad-p53 MDM2: 9% of the nucleolus, there was a nearly complete correlation
Ad-ARF ARF: weak
(more than 95 of 100 cells counted) between ARF’s nu-12. Ad-MDM2 p53: 9%
cleoplasmic localization and positive MDM2 staining. InAd-p53
Saos-2 cells, where p53 is mutated and undetectablepCMV-ARF
13. Ad-MDM2 p53: 52% amounts of MDM2 are expressed, E2F1-induced ARF
Ad-p53 was almost exclusively localized to the nucleolus (about
CMV-ARF1-64 99 out of every 100 cells counted). Cells showing this
14. Ad-MDM2 p53: 45%
localization also stained negatively for MDM2. TheseAd-p53
observations support the notion that MDM2 relocatesCMV-ARF1-82
ARF from the nucleolus to the nucleoplasm. They also15. Ad-MDM2 p53: 60%
Ad-p53 suggest the possibility that either E2F1 itself or E2F1
pCMV-ARF1-86-p1673-156 through ARF could positively regulate MDM2, because
16. Ad-MDM2 p53: 38% all ARF-negative (i.e., uninfected) NHF-1 cells also
Ad-p5
stained negatively for MDM2.pCMV-ARF1-94-p1680-156
a One hundred single, double, or triple positive cells from each infec- ARF Colocalizes with MDM2 in the Nucleoplasmtion were examined for the subcellular localization of each ectopi-
to Form Nuclear Bodiescally expressed protein by indirect immunofluorescence.
Close examination of both MDM2 and ARF by immuno-b Only a small population of cells (z5%) is double positive for both
proteins. fluorescence staining revealed discrete punctate dots
c From each infection, 100 (infections 8 and 9), 65 (infection 10), and in Ad-E2F1-infected NHF-1, U2-OS, and SJSA cells, but
(infection 11), 100 (12), 50 (13), 40 (14, 15, and 16) heterokaryons not in Saos-2 cells (Figure 3C; referred to as nuclear
were examined. In all double infections, expression of both proteins
bodies hereafter), indicating that MDM2 itself was alsoin the heterokaryons examined were verified by double staining. In
relocalized following ARF’s relocation. The MDM2 andthe triple infection, coexpression of all three proteins in the hetero-
ARF nuclear bodies display identical punctate patterns,karyons were judged by the appearance of discrete nuclear bodies
and positive staining for two of three proteins. suggesting MDM2 and ARF colocalized in the nuclear
bodies, which were not seen in control virus–infected
cells (Figure 3C) or in ARF-negative (uninfected) cells in
the same viewing field of Ad-E2F1-infected populations.
This confirmed the relocation of MDM2 in the nucleusresulted in a significant reduction of p53-positive cells
in the population. When coinfected with Ad-p53 and Ad- caused by E2F1-induced ARF expression. Similar MDM2
nuclear bodies were also detected using a differentMDM2, less than 5% of the cells were positive for p53.
However, when cells were either singly infected with a-MDM2 antibody recognizing a different epitope (see
Figure 5A), eliminating the possibility of nonspecificAd-p53 or doubly infected with Ad-p53 and Ad-ARF at
the same m.o.i., more than 80% of the cells were p53 detection of an unrelated subnuclear structure by the
a-MDM2 antibody. In contrast, no MDM2 nuclear bodiespositive (Table 1 and data not shown). In these p53 and
MDM2 double positive cells, the nuclear localization of were detected in Saos-2 cells, and E2F1-induced ARF
remained in the nucleolus, reinforcing the notion thatboth proteins is indistinguishable from that seen in singly
infected cells (Figure 3B, column 4). Coexpression of relocation of both ARF (moving out the nucleolus) and
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MDM2 (forming nuclear bodies) depends on the simulta- interact with p53 and was further confirmed by the use
of MDM2-binding deficient ARF deletion mutants (seeneous expression of both proteins.
below). The nuclear body structure was detected in a
high percentage of triple positive cells (nearly 90%, Ta-p53 Facilitates the Formation of and Associates
ble 1), not a small population of “aberrant” cells, and iswith MDM2-ARF Nuclear Bodies
a general phenomenon of the three proteins’ coex-ARF-MDM2 nuclear bodies were not detected in HeLa
pression.cells infected with Ad-MDM2 (Figure 3A) or in Saos-2
cells coinfected with Ad-ARF and Ad-MDM2 (Figure 3B,
column 6) where both proteins are apparently expressed Formation of ARF-MDM2-p53 Nuclear Bodies
at high level. These observations suggest that ARF and Requires Both Domains of ARF Protein
MDM2 may not efficiently form nuclear bodies alone, We next determined whether alteration of ARF’s nucleo-
so we examined the subcellular localization of p53. Re- lar localization regulatory domain in exon 2 affects the
markably, nearly all NHF-1, U2-OS, and SJSA cells in relocalization and nuclear body formation with p53 and
which ARF and MDM2 colocalized formed nuclear bod- MDM2. U2-OS cells were triply transfected with plas-
ies. p53 was also relocalized, from an even distribution mids expressing p53, MDM2, and wild-type or mutant
in the nucleoplasm to colocalization with MDM2 and ARF proteins. Deletion of ARF’s exon 1b–encoded
ARF in the nuclear bodies (Figure 3C, a-p53 staining). N-terminal domain (ARF65–132), which still retains most of
Punctate p53 staining patterns were not detected in the ARF protein in the nucleolus, completely abrogated
control cells, which also stained negatively for ARF and its colocalization with MDM2 and p53 and the formation
MDM2, or in p53-negative Saos-2 cells. Coexpression of of ARF-MDM2-p53 bodies (column 2). This is consistent
p53, MDM2, and ARF by adenovirus-mediated infection with both ARF’s N terminus being required for interac-
(Figure 4A) or plasmid-mediated transfection (Figure 4B, tion with MDM2 and MDM2’s being required to bridge
column 1) in p53-negative Saos-2 cells showed dramatic ARF’s interaction with p53. Deletion of either the entire
subcellular relocalization of all three proteins to form exon 2–encoded C-terminal domain (ARF1–64, column 3)
discrete nuclear bodies. In the majority of triple positive or the final 50 amino acid residues (ARF1–84, column 4),
cells, both p53 and MDM2 were no longer evenly distrib- while still capable of binding to MDM2 (Zhang et al.,
uted in the nucleus, but instead formed punctate dots 1998), disrupts ARF’s nucleolar localization and the for-
like ARF, which was no longer in the nucleolus (Figure mation of discrete triprotein nuclear bodies. Thus, both
4A). All three proteins displayed identical punctate the MDM2-binding activity, encoded by the exon 1b,
patterns, indicating that p53, MDM2, and ARF were colo- and the nucleolus-localizing activity residing in the exon
calized. The nuclear bodies in triply infected or trans- 2 domain are important for ARF, p53, and MDM2 to form
fected cells are clearer than those detected in E2F1- nuclear bodies.
infected cells, presumably due to the elevated protein
levels from ectopic expression. Relocation of all three
proteins to these structures was a rapid process. As ARF Blocks Nuclear Export of p53 and MDM2
Relocalization of MDM2 and p53 in the nucleus by ARFearly as 12 hr after infection, ARF’s characteristic nucle-
olar staining disappeared and tiny punctate staining of led us to test by heterokaryon assay whether ARF blocks
the nuclear export of either or both protein, therebyp53, MDM2, or ARF became visible (data not shown).
To exclude the possibilities that these nuclear bodies stabilizing p53. We first confirmed that both MDM2 and
p53 could efficiently shuttle between the nucleus andare nucleoli or “nucleolus break-down products,” we
stained triply infected cells with an antibody to the major the cytoplasm (Figure 5A, columns 1 and 4). In cells
coinfected with p53 and ARF adenoviruses, the ARFhuman nucleolar protein, B23 (nucleophosmin). The
a-B23 antibody staining exhibited a pattern matching protein remained in the nucleolus, while nucleo-cyto-
plasmic shuttling of p53 was not affected by the coex-that of the nucleolus, but not the ARF-MDM2-p53 nu-
clear bodies (data not shown). pression of ARF (Figure 5A, columns 2 and 5; Table 1).
Weak ARF staining, barely distinguishable from back-To rule out the formation of this novel ARF-MDM2-
p53 nuclear body structure being a cell type–specific ground, was detected in murine nuclei, indicating that
ARF, unlike p53 and MDM2, was not actively shuttlingphenomena, we examined localization of the three coex-
pressed proteins in U2-OS, NHF-1, and IMR90 cells. The between the nucleus and the cytoplasm. Following coin-
fection, in p53 and MDM2 double positive heterokary-same discrete nuclear bodies were observed in all three
cell lines following triple viral infection (Figure 4A). ARF- ons, both p53 and MDM2 shuttle between the nucleus
and cytoplasm (Figure 5A, columns 1 and 4). The numberMDM2-p53 nuclear bodies were also observed in cells
triply transfected with plasmid DNAs expressing each of p53-positive murine nuclei in MDM2-p53-infected
heterokaryons (i.e., human nuclei double positive forof the three proteins (Figure 4B, column 1). This, plus
the fact that nuclear bodies were not observed in cells both MDM2 and p53) is, however, significantly lower
than in heterokaryons infected with p53 alone (data notsingly, doubly, or control infectioned, eliminated the
possibility that formation of nuclear bodies was caused shown) or ARF-p53 double infected heterokaryons (Ta-
ble 1). We interpret this observation as the result ofby viral infection per se. In cells doubly infected with
p53 and ARF viruses, p53 and ARF did not colocalize MDM2-mediated p53 degradation in the cytoplasm, pre-
venting reentry of p53 from the fused cytoplasm intoto form this discrete structure, nor did they change sub-
cellular localization (Figure 3B, column 5), suggesting the murine nuclei. Performing a heterokaryon assay to
determine nucleo-cytoplasmic shuttling of MDM2 andthat nuclear body formation is MDM2 dependent. This
is consistent with MDM2’s being required for ARF to ARF proteins when coexpressed was not possible due
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Figure 4. Formation of ARF-MDM2-p53 Nu-
clear Bodies Requires Both the Exon 1b and
Exon 2 Domains of ARF
(A) Different cells were triply infected with ad-
enoviruses expressing p53, MDM2, and ARF
as indicated. Cells were fixed and stained as
described before.
(B) U2-OS cells were triply transfected with
plasmid DNAs expressing wild-type MDM2,
wild-type p53, and either wild-type or mutant
ARF proteins. Cells were fixed and stained
as described before.
to the lack of an antibody from a third species to either MDM2 nuclear export and the formation of ARF-MDM2-
p53 nuclear bodies, indicating a causal relationship be-protein.
tween the two events.When cells were triply infected with adenoviruses ex-
pressing p53, MDM2, and ARF, nuclear export of both
p53 and MDM2 was not detected (Figure 5A, columns Tumor-Derived Mutations Reduce ARF’s Ability
3 and 6; Table 1). Facilitated by the highly efficient ade- to Block p53 Nuclear Export
noviral infection, a large portion of the cells (more than Finally, we determined whether a decrease in ARF’s
75%–80% by visual estimation) expressed all three pro- ability to stabilize p53 is related to ARF’s ability to block
teins, allowing us to examine a large number of triple p53 nuclear export. U2-OS cells were infected with
positive heterokaryons. In a majority of heterokaryons MDM2 and p53 adenoviruses to provide a uniform back-
(.90%), where expression of all three proteins was de- ground of both proteins in the cell population. Then,
termined by positive immunostaining of p53 and either infected cells were transfected individually with plas-
ARF (data not shown) or MDM2 (Figure 5A, columns 3 mids expressing wild-type or mutant ARF proteins (myc
and 6) in conjunction with the appearance of nuclear epitope tagged). The effect of each mutation on ARF’s
bodies, nuclear export of both p53 and MDM2 was not cellular localization was determined by indirect immu-
detected (Figure 5A, columns 3 and 6; Table 1). There nofluorescence staining, and p53 nuclear export was
determined by heterokaryon assay. As expected, theis a complete correlation between the loss of p53 and
Functional Alteration of ARF by Cancer Mutations
587
Figure 5. Formation of ARF-MDM2-p53 Nuclear Bodies Blocks Nuclear Export of p53 and MDM2
(A) Saos-2 and U2-OS cells were doubly or triply infected with adenoviruses expressing p53, MDM2, and ARF as indicated. Cells were washed
and fused with murine NIH-3T3 cells 24 hr after infection, while de novo protein synthesis was blocked by cycloheximide. Cells were fixed
and stained with antibodies to p53, MDM2, ARF, and human Ku antigen followed by staining with secondary antibodies 45 min after fusion.
The heterokaryons were photographed.
(B) U2-OS cells were first doubly infected with Ad-p53 and Ad-MDM2 and then transfected with a plasmid expressing either wild-type or
mutant ARF as indicated. The subsequent heterokaryon assay is the same as described above.
deletion of the exon 2 domain (ARF1–64, column 2), the cytoplasm as well as to murine nuclei. In only about half
the population of heterokaryons (p53 and ARF doubleC-terminal 30 residues (ARF1–82, column 3), a frameshift
mutation at ARF codon 86 (ARF1–86-p1673–156, column 4), positive) was p53 evidently accumulated in the murine
nuclei (Figure 5B; Table 1), indicating that the mutationsand a frameshift mutation at ARF codon 94 (ARF1–94-
p1680–156, column 5) all disrupted ARF’s normal nucleolar significantly reduced, but not completely abolished,
ARF’s ability to block p53 nuclear export. These resultslocalization, causing significant diffusion of ARF to the
Molecular Cell
588
are consistent with a reduction, but not complete loss,
of ARF’s ability to stabilize p53 (Figure 2C).
Discussion
ARF, MDM2, and p53 Form Novel Nuclear Bodies
We have shown here that p53, MDM2, and ARF proteins,
when induced to express endogenously or overex-
pressed ectopically, relocalize rapidly in the nucleus to
form a novel subnuclear structure. Three lines of evi-
dence support the genuineness and physiological rele-
vance of ARF-MDM2-p53 nuclear bodies: the depen-
dency of nuclear body formation on the integrity of
ARF-MDM2-p53 triprotein interaction, the induction by
a physiological signal (E2F1) at normal levels of expres-
sion, and an association with a blockage of p53 nuclear
export. The nuclear bodies formed by p53, MDM2, and
ARF, although variable in size, are clearly visible by light
microscopy, which suggests that they likely contain a
large number of additional proteins and are potentially
associated with chromatin. Evidence suggests that p53
may be directly involved in the regulation of DNA synthe-
sis during either DNA replication or repair. Given their
discrete and higher order structure, we suspect it is
unlikely that the ARF-MDM2-p53 nuclear bodies are
formed to upregulate the sequence-specific transacti- Figure 6. Regulation of p53 Protein Stability by Nuclear Export and
Comparison of DNA Damage- and Oncogene-Induced p53 Stabili-vating activity of p53. Instead, they may function in a
zationDNA synthesis– or chromatin structure–related event.
(A) p53 and MDM2 proteins shuttle between the nucleus and cyto-The molecular architecture of the ARF-MDM2-p53 body
plasm (Freedman and Levine, 1998; Roth et al., 1998; Stommel etis yet to be determined but is reminiscent the nuclear
al., 1999). MDM2 targets p53 for degradation in the cytoplasm.
bodies formed by the promyelocyte leukemia protein, Coexpression of ARF results in formation of discrete ARF-MDM2-
PML (Dyck et al., 1994; Weis et al., 1994). Like the ARF- p53 nuclear bodies and blocks nuclear export of both p53 and
MDM2-p53 nuclear bodies, the PML body also contains MDM2.
(B) Comparison of DNA damage–induced and oncogene-induceda potentially large number of additional proteins. Among
p53 accumulation. DNA damage increases the activities of potentialseveral proteins that have been found to colocalize with
p53 kinases to phosphorylate sites located within the N-terminalPML are Rb (Alcalay et al., 1998) and CBP/p300 histone
MDM2-binding domain of p53 (e.g., Ser-15). DNA damage–induced
acetyltransferases (Lamorte et al., 1998), both of which phosphorylation at Ser-15 alleviates the association of p53 with
have been reported to associate with MDM2 directly (Xiao MDM2 (Shieh et al., 1997) and results in p53 stabilization and activa-
et al., 1995; Grossman et al., 1998; Hsieh et al., 1999). tion. Oncogenes activate ARF gene expression. In the presence of
MDM2 and p53, ARF forms discrete nuclear bodies with these two
proteins and blocks their nuclear export, leading to p53 stabilization.
Stabilizing p53 and MDM2 by Blocking
Nuclear Export
MDM2 plays a critical role in regulating the stability of resulted in a decrease of MDM2’s half-life and an in-
crease in p539s stability (Zhang et al., 1998). These con-p53 protein by targeting p53 for degradation (Haupt et
al., 1997; Kubbutat et al., 1997). MDM2-targeted p53 flicting observations imply that ARF may antagonize
MDM2 function through different mechanisms or thatdegradation appears to occur in the cytoplasm (Freed-
man and Levine, 1998; Roth et al., 1998). As a result, the MDM2-ARF interaction may be affected by viral
transformation. We have not yet determined whether inblocking p53 and/or MDM2 nuclear export would effi-
ciently stabilize p53. Fulfilling this prediction, we have HeLa cells p53, MDM2, and ARF proteins also relocalize
to form similar nuclear bodies or whether ARF alsofound that ARF can block nuclear export of both p53
and MDM2 (Figure 5A). Whether MDM2 is also regulated blocks MDM2 nuclear export. Nevertheless, in nonvirally
transformed cells, both normal and tumorgenic, it ap-at protein level is not very clear at present. Ectopic
expression of ARF or activation of ARF expression by pears that ARF protein blocks MDM2 nuclear export
and stabilizes MDM2.E1A or myc induces the accumulation of MDM2 protein
(de Stanchina et al., 1998; Kamijo et al., 1998; Stott et
al., 1998; Zindy et al., 1998). Blocking nuclear export of Stabilizing p53 by Two Distinct Pathways?
Block of p53 nuclear export is closely correlated withMDM2 (Figure 5) suggests that nucleo-cytoplasm shut-
tling may also regulate the level of MDM2. If so, it will the relocation and formation of discrete nuclear bodies
containing p53, MDM2, and ARF. These nuclear bodiesbe interesting to determine how MDM2 avoids its own
degradation prior to targeting p53 for degradation in the were not detected in cells coexpressing p53 and MDM2
with mutant ARF that lacks the N-terminal MDM2-bind-cytoplasm. In HeLa cells, however, we have previously
found that coexpression of ARF with MDM2 and p53 ing domain (Figure 4B), nor were they observed in cells
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coexpressing p53 and ARF, without MDM2 (Figure 3B), and cause cytoplasmic diffusion of ARF protein (Figures
2). This disruption of normal subcellular location is asso-indicating that formation of p53 nuclear bodies is depen-
dent on MDM2. ARF is not induced by DNA damage, ciated with a reduced ability to stabilize p53 (Figure 2)
and block p53 nuclear export (Figure 5). Together, thesenor does DNA damage–induced p53 activation require
ARF (Kamijo et al., 1997). Instead, ARF gene expression data demonstrate a biochemical and biological function
residing in the exon 2 domain of ARF and indicate thatis activated by proliferation-promoting oncogenes such
as Myc (Zindy et al., 1998), E1A (de Stanchina et al., mutations within exon 2 could target ARF in addition to
INK4a, or even ARF alone, as in the case of Arg-98, for1998), oncogenic ras (Palmero et al., 1998), and E2F1
(Bates et al., 1998), which place ARF on the proliferation- functional inactivation or reduction.
activated p53 checkpoint pathway (reviewed in Sherr,
Experimental Procedures1998). In contrast, DNA damage–induced p53 phosphor-
ylation at Ser-15 and accumulation is correlated with an
Plasmid Constructsattenuation of p53-MDM2 interaction (Shieh et al., 1997).
Mammalian expression plasmids expressing wild-type ARF, the
While it still remains to be determined whether or not exon 1b–encoded N terminus (residues 1 to 64), and the exon
the DNA damage–induced p53 modification affects p53 2–encoded C terminus (residues 65 to 132) were described pre-
viously (Zhang et al., 1998). Additional ARF deletion and point mu-nuclear export, the DNA damage–activated signaling
tants were constructed by PCR-mediated mutagenesis. All mutantspathway stabilization of p53 is distinct from that of onco-
were confirmed by direct DNA sequencing.gene-activated p53 stabilization in one additional key
aspect: the former stabilizes p53 by dissociating it from
Cell Lines, Cell Culture, and Transfection
interaction with MDM2, and the latter may require MDM2 HeLa, U2-OS, Saos-2, IMR90, and NHF-1 cells were obtained from
to stabilize p53. Furthermore, not only the upstream either the ATCC or the UNC Lineberger Tissue Culture Facility. JAR
(ATCC HTB-144) and SJSA (formally OSA-CL, ATCC CRL-2098) cellssignals (DNA damage versus oncogenes such as E1A,
were provided by Dr. Jiangdong Chen (Louisiana State University).E2F, myc, and ras that activate ARF expression) and
Procedures and conditions for cell culture, transfections, metabolicthe mediators (kinases versus ARF) are different; the
labeling, immunoprecipitation, and immunoblotting were previouslystructural components of the resultant p53 are also dif-
described (Zhang et al., 1998).
ferent between these two pathways: phosphorylated,
free p53 versus ARF-MDM2 associated p53 (Figure 6B). Indirect Immunofluorescence
Cultured cells were seeded in 6-well plates, transfected with plasmidOne might therefore further speculate that the functional
DNA (1 mg/well), or infected with adenoviruses. Cells were washedoutcome might be different as well between these two
three times with PBS and fixed in PBS containing 3% formaldehydepathways. For example, one pathway may preferentially
for 10 min, 24 hr after transfection or infection. After fixation, the cellscause cell cycle arrest by removing MDM2-imposed in-
were washed twice with PBS, permeabilized in cold PBS containing
hibition on the sequence-specific transcriptional activity 0.2% Triton X-100 for 5 min, and incubated with PBS containing
of p53, while the other induces apoptosis through forma- 0.5% BSA as a blocking agent for 30 min prior to incubation with
the blocking buffer containing the primary antibody for 1 hr. The cellstion of the higher order nuclear bodies.
were then incubated with an appropriate fluorochrome-conjugated
secondary antibody for 30 min. Between different antibody incuba-Frequent Oncogenic Mutations in Exon 2 of
tions, the cells were washed three times with PBS. Stained cells
the ARF-INK4a Locus Also Target ARF were covered by anti-fluorescent mounting medium (DAKO) and
The ARF-INK4a locus is frequently altered in a wide examined with an Olympus IX70 microscope fitted with appropriate
fluorescence filters. Dilution of primary antibodies are 1 mg/ml forrange of human cancers, with an estimated frequency
ARF, 0.2 mg/ml for MDM2, 0.2 mg/ml for p53, and 4 mg/ml for Ku.close to that of p53 mutations. In addition to homozy-
All fluorochrome-conjugated secondary antibodies are diluted at 10gous deletions that disrupt both INK4a and ARF genes,
mg/ml.frequent mutations also occur in exon 2. Those muta-
tions include microdeletions, insertions, and single nu- Antibodies
cleotide substitutions, most of which cluster at the 59 The affinity purified rabbit polyclonal a-human ARF antibody was
previously described (Zhang et al., 1998). Affinity purified rabbitportion of exon 2, which is shared by ARF and INK4a,
polyclonal antibodies to human MDM2 (N-20, Santa Cruz), humanwhich are predicted to alter both INK4a and ARF. Since
nucleolar protein B23 (C-19, Santa Cruz), goat polyclonal antibodyoverexpression of the exon 1b–encoded ARF N terminus
to human p53 (FL393, Santa Cruz), mouse monoclonal antibodiesalone is sufficient to cause cell cycle arrest (Quelle et al.,
to p53 (clone PAb421, Oncogene Science), to myc (clone 9E10.3,
1997), the assumption has been that cancer-associated NeoMarkers), to HA (clone 12CA5, Boehringer Mannheim), to human
mutations within exon 2 selectively target the INK4a MDM2 (clone SMP14, NeoMarkers), to human Ku nuclear antigen
(p80, clone 111, NeoMarkers), and rhodamine Red–, fluoresceingene, but not ARF, for inactivation. We have found that
isothiocyanate (FITC)–, 7-amino-4-methylcoumarin-3-acetic acidthe C-terminal domain of human ARF is required for its
(AMCA)–conjugated donkey secondary antibodies (Jackson Immu-nucleolar localization (Figure 1), for the formation of
noResearch Laboratories) were purchased commercially.ARF-MDM2-p53 nuclear bodies (Figure 4), for the full
activity of ARF to stabilize p53 (Figure 2), and for Adenovirus
blocking p53 nuclear export efficiently (Figure 5). We Production of ARF adenovirus will be described elsewhere (W. Yar-
brough, M. Bessho, S. Neil and Y. X., unpublished data). For viralhave further identified a small sequence within the
infection experiments, exponentially growing cells were infectedC-terminal domain, between residues 83 to 101, that is
with adenovirus in DMEM media supplemented with 2% FBS andnecessary and sufficient for localizing ARF to the nu-
were incubated for 2 hr in a 378C incubator with 5% CO2. Infectedcleus and nucleolus. Tumor-derived frameshift muta-
cells were then washed with prewarmed PBS and replaced with
tions that eliminated this sequence or base substitution fresh DMEM supplemented with 10% FBS until cell lysis or fixation.
mutations at a conserved residue (Arg-98) within this For experiments presented in Figure 3, 2 hr after MDM2 adenovirus
infection, cells were washed with prewarmed PBS and replacedsequence disrupt ARF’s normal nucleolar localization
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with fresh DMEM supplemented with 10% FBS. After another 2 hr Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes
the rapid degradation of p53. Nature 387, 296–299.of culturing, the cells were transfected with plasmid DNA expressing
appropriate proteins. The cells were lysed 24 hr after transfection, Hsieh, J.-K., Chan, F.S.G., O’Connor, D.J., Mittnacht, S., Zhong, S.,
and the expression of each protein was determined by immu- and Lu, X. (1999). RB regulates the stability and the apoptotic func-
noblotting. tion of p53 via MDM2. Mol. Cell 3, 181–193.
Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K.,
Heterokaryon Assay Tavitgian, S.V., Stockert, E., Day, R.S., Johnson, B.E., and Skolnick,
Human Saos-2 or U2-OS was singly infected with individual adeno- M.H. (1994). A cell cycle regulator potentially involved in genesis of
viruses or coinfected with different combinations. After 2 hr of incu- many tumor types. Science 264, 436–440.
bation with viruses, cells were washed twice with prewarmed PBS
Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R.,
to remove uninfected viruses and continually cultured for 12 hr to
Ashmun, R.A., Grosveld, G., and Sherr, C.J. (1997). Tumor suppres-
allow protein synthesis. The cells were then trypsinized, mixed with
sion at the mouse INK4a locus mediated by the alternative reading
murine NIH-3T3 cells at a ration of 1:1, and seeded into a new dish. frame product p19ARF. Cell 91, 649–659.
The cells were rinsed once with PBS 12 hr after reseeding and
Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M., andcovered with solution of 50% (w/v) polyethylene glycol (PEG 3000,
Sherr, C.J. (1998). Functional and physical interaction of the ARFSigma) for 2 min at 378C to induce cell fusion. After washing twice
tumor suppressor with p53 and MDM2. Proc. Natl. Acad. Sci. USAwith PBS to remove the PEG, fused cells were continually cultured
95, 8292–8297.in the DMEM/10% FBS media for another 45 min. Cycloheximide
Koh, J., Enders, G.H., Dynlacht, B.D., and Harlow, E. (1995). Tumor-(50 mg/ml, Sigma) was added to the culture 15 min prior to and
derived p16 alleles encoding proteins defective in cell-cycle inhibi-immediately after cell fusion to block de novo protein synthesis.
tion. Nature 375, 506–510.Subsequent cell fixation, permeablization, and immunostaining fol-
lowed conventional immunofluorescence procedures. The cells Kubbutat, M.H.G., Jones, S.N., and Vousden, K.H. (1997). Regulation
were doubly or triply stained with a mouse antibody recognizing of p53 stability by Mdm2. Nature 387, 299–303.
human—but not murine Ku nuclear antigen—to distinguish human Lamorte, V.J., Dyck, J.A., Ochs, R.L., and Evans, R.M. (1998). Local-
and murine nuclei, together with a rabbit antibody to ARF or MDM2 ization of nascent RNA and CREB binding protein with the PML-
and a goat antibody to p53. containing nuclear body. Proc. Natl. Acad. Sci. USA 95, 4991–4996.
Levine, A.J. (1997). p53, the cellular gatekeeper for growth and divi-
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